AdageneFRA:978 42 Market Cap is €229.92 Mil as of Jun. 28, 2026. GuruFocus rates FRA:978 with a GF Score™ of 42/100 and a GF Value™ of €11.74. The stock has 5 warning signs investors should review. Among 1,429 Biotechnology companies, Adagene ranks better than 62.77% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Adagene's share price for the quarter that ended in Dec. 2025 was €1.47. Adagene's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 47.39 Mil. Therefore, Adagene's market cap for the quarter that ended in Dec. 2025 was €69.66 Mil.
Adagene's quarterly market cap
declined
from Dec. 2024 (€85.27 Mil) to Jun. 2025 (€75.41 Mil) and
declined
from Jun. 2025 (€75.41 Mil) to Dec. 2025 (€69.66 Mil).
Adagene's annual market cap
increased
from Dec. 2023 (€65.73 Mil) to Dec. 2024 (€85.27 Mil) but then
declined
from Dec. 2024 (€85.27 Mil) to Dec. 2025 (€69.66 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Adagene's Enterprise Value for Today is €170.95 Mil.
Adagene (FRA:978) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Adagene Market Cap Related Terms
Adagene Market Cap Historical Data
* Premium members only.
The historical data trend for Adagene's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:978 vs CNTX, TARA, NVCT: Market Cap Comparison
For the Biotechnology subindustry, Adagene's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adagene Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Adagene's Market Cap distribution charts can be found below:
* The bar in red indicates where Adagene's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Adagene's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adagene (FRA:978) has a Market Cap of €229.92 Mil as of Jun. 28, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Adagene and its competitors. According to the industry distribution chart, Adagene ranks #532 out of 1429 companies in the Biotechnology industry, placing it in the top 37.2%.
Is Adagene's Market Cap too high?
Adagene's current Market Cap is €229.92 Mil. Based on the distribution chart, Adagene ranks #532 out of 1429 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Adagene has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does Adagene's Market Cap compare to CNTX and TARA?
According to the Biotechnology industry distribution chart, Adagene ranks #532 out of 1429 companies for Market Cap. This puts Adagene in the upper half of its industry. The industry median Market Cap is 112.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 112.70, based on 1,429 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Adagene and its competitors. For the Biotechnology industry, the median Market Cap is 112.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Adagene's current Market Cap is €229.92 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adagene stock overvalued right now?
Adagene (FRA:978) has a current Market Cap of €229.92 Mil. The stock's GF Value™ is €11.74, compared to a current price of €3.48 — trading 70.4% below its estimated fair value. The current Market Cap is €229.92 Mil. Adagene's overall GF Score™ is 42/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Adagene (FRA:978), the current Market Cap is €229.92 Mil as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Adagene (FRA:978) Overvalued in 2026?
Based on GuruFocus' analysis, Adagene stock appears to be undervalued.
The current stock price of €3.48 is trading 70.4% below its estimated GF Value™ of €11.74.
Key valuation signals for FRA:978:
Market Cap: €229.92 Mil
GF Value™: €11.74 vs. price of €3.48 (70.4% below fair value)
No single metric tells the full story. See the FRA:978 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.
42GF Score
Get the complete analysis for FRA:978
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:978 has been successfully added to your 
